SCHEMBL14801905

SCHEMBL14801905

CNCCc1cn(CCN2CCC(C)CC2)c2ccc(Cl)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 4/20 0.42
PRMT6 Q96LA8 4/20 0.42
PRMT1 Q99873 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
CNR2 P34972 4/20 0.39
SIGMAR1 Q99720 3/20 0.39
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1120694 0.88 CACNB4 (0.47) LMNASIGMAR1KCNH2
SCHEMBL1120458 0.81 ALDH1A1 (0.48) L3MBTL1MEN1ALDH1A1LMNAKMT2A
SCHEMBL1120436 0.81 CNR1 (0.38) MEN1KMT2ACNR2KCNH2
SCHEMBL1120592 0.78 VEGFA (0.42) MEN1LMNAKMT2A
SCHEMBL27811435 0.78 CNR2 (0.36) CNR2DRD2
Tert-Butyl Formate SCHEMBL27811436 0.77 CNR2 (0.35) CYP1A2CYP2D6GAAKDM4EALDH1A1
SCHEMBL1120393 0.75 SNCA (0.35) CNR2KCNH2
SCHEMBL14302712 0.74 SNCA (0.53) KMT2AKCNH2
SCHEMBL1120388 0.74 ACLY (0.44) L3MBTL1MEN1KMT2ASIGMAR1
SCHEMBL1120695 0.74 KCNH2 (0.48) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469641-B2 Pyrido[3,4-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-10-18 US disclosed
US-20130079352-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079352-A1 PYRIDO[3,4-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C CARM1 3386/4885PRMT6 1718/4885PRMT1 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.